ZVRA: חוב לטווח קצר של החברה Zevra Therapeutics

This price chart for Zevra Therapeutics (ZVRA) illustrates the asset's dynamics, where the indicator stands at 0.00. The company generates revenue through the development and sale of drugs for rare brain and nerve pathologies, as well as through licensing royalties. Specializing in orphan drugs allows the company to scale profits, as the growing patient population offsets research and development costs more rapidly.

Short-term debt for Zevra Therapeutics (ZVRA) reflects a liquidity dependence on external financing during the drug commercialization phase. This metric aggregates all obligations maturing within twelve months, measuring the pressure on working capital. Monitoring short-term liabilities allows for an assessment of loan refinancing efficiency in the event of delayed insurance payments. An increase in this indicator signals a risk of declining net income. The stability of the chart confirms the resilience of the capital structure.